Objective: To study the relationship of liver function index alanine aminotransferase and aspartate aminotransferase ratio (LSR) with clinicopathological factors in patients with gastric cancer and its clinical significance in predicting the survival of patients. Methods: A retrospective case-control study was used. Retrospective analysis was conducted on 891 patients with advanced gastric cancer who underwent gastric cancer surgery at the Gastrointestinal Surgery Department of Harbin Medical University Cancer Hospital from January 2007 to December 2010, having complete postoperative clinicopathological and follow-up data. Case inclusion criteria: (1) preoperative definite diagnosis of gastric cancer, residual gastric cancer and other gastric tumors were excluded; (2) no neoadjuvant therapy before surgery; (3) no other serious diseases such as acute coronary heart disease, cirrhosis, chronic renal failure, etc.; (4) radical gastrectomy was performed, palliative treatment or open laparotomy cases were excluded; (5) complete postoperative pathological data, complete follow-up information; (6) cause of death was associated with gastric cancer. Blood examination was performed during hospitalization. The best cut-off points of LSR, hemoglobin, lymph node metastasis rate, maximum diameter of tumors, alkaline phosphatase, glutamyl transpeptidase, total bilirubin and lactate dehydrogenase were obtained by using receiver operating characteristic curve(ROC). Patients were divided into two groups according to best LSR cut-off points. The relationship between LSR and clinicopathological factors was analyzed, and the overall survival rate of different LSR groups was compared. Relevant clinical factors and LSR were included in the univariate and multivariate survival analysis using the Cox method. Results: The best cut-off point of LSR in ROC curve was 1.43, and 682 cases in LSR<1.43 group, 209 cases in LSR≥1.43 group. The best cut-off points of hemoglobin, lymph node metastasis rate, maximum diameter of tumors, alkaline phosphatase, glutamyl transpeptidase, total bilirubin and lactate dehydrogenase were 130.2 g/L, 18.0%, 4.75 cm, 68.1 U/L, 16.55 U/L, 5.58 μmol/L and 135.8 U/L, respectively. Between patients with LSR<1.43 and LSR≥1.43, age (χ(2)=4.412, P=0.036), depth of tumor invasion (χ(2)=64.306, P<0.001), histological type (χ(2)=8.026, P=0.005), alkaline phosphatase (χ(2)=8.217, P=0.004), glutamyl transpeptidase (χ(2)=33.207, P<0.001), total bilirubin (χ(2)=14.012, P<0.001) and lactate dehydrogenase (χ(2)=63.630, P<0.001) were significantly different. The 1-, 3- and 5-year survival rates of LSR<1.43 group and LSR≥1.43 group were 70.8%, 31.3%, 25.0% and 64.9%, 24.4%, 11.3% respectively, whose difference was significant (χ(2)=10.140, P=0.001). Univariate analysis showed that age, hemoglobin, TNM stage, depth of invasion, lymph node metastasis rate, lymph node metastasis, histological type, maximum diameter of tumors, glutamyl transferase, total bilirubin and LSR were associated with overall survival of gastric cancer (all P<0.05). Multivariate analysis showed that tumor TNM stage (HR=1.605, 95%CI: 1.332 to 1.936, P<0.001), tumor invasion depth (HR=1.299, 95%CI: 1.168 to 1.445, P<0.001), lymph node metastasis rate (HR=2.400, 95%CI:1.873 to 3.076, P<0.001), lymph node metastasis (HR=1.263, 95%CI: 1.106 to 1.478, P=0.007), maximum tumor diameter (HR=1.375, 95%CI: 1.134 to 1.669, P=0.001), and LSR (HR=1.427, 95%CI: 1.190 to 1.711, P<0.001) were independent risk factors for the prognosis of patients with gastric cancer. Conclusions: LSR is an independent risk factor for the prognosis of gastric cancer patients, and the detection is simple and easy. It is a potential marker for the prognosis of gastric cancer. Therefore, in the preoperative comprehensive management stage, it should be possible to restore and improve the liver function in order to obtain a better prognosis of gastric cancer and prolong the survival time of patients.
目的： 研究胃癌患者肝功能指标丙氨酸氨基转移酶和天冬氨酸氨基转移酶比值（LSR）与临床病理因素的关系及其对预测患者生存期的临床意义。 方法： 采用回顾性病例对照研究的方法。回顾性分析2007年1月至2010年12月期间在哈尔滨医科大学附属肿瘤医院胃肠外科行胃癌手术治疗、且术后病理及随访资料完整的891例进展期胃癌患者的临床资料。病例纳入标准：（1）术前明确诊断为胃癌，排除残胃癌及胃其他肿瘤；（2）术前未行新辅助治疗；（3）不合并其他严重疾病如急性冠心病、肝硬化、慢性肾衰等；（4）行胃癌根治术，排除姑息治疗或开腹探查病例；（5）术后病理资料完全，随访信息完整；（6）死亡原因与胃癌相关。取患者入院时采血结果，利用受试者工作特征曲线（ROC）分别对LSR、血红蛋白、淋巴结转移率、肿瘤最大直径、碱性磷酸酶、谷氨酰转肽酶、总胆红素和乳酸脱氢酶取最佳截点。根据LSR截点分组，分析LSR与临床病理因素之间的关系，对不同LSR组别进行总体生存率的比较。并将相关临床因素和LSR纳入单因素和多因素Cox生存分析。 结果： LSR的ROC曲线最佳截点为1.43，LSR<1.43组682例，LSR≥1.43例209例。血红蛋白、淋巴结转移率、肿瘤长径、碱性磷酸酶、谷氨酰转肽酶、总胆红素和乳酸脱氢酶的ROC曲线最佳截点分别为130.2 g/L、18.0%、4.75 cm、68.1 U/L、16.55 U/L、5.58 μmol/L和135.8 U/L。LSR<1.43组与LSR≥1.43组患者比较，年龄（χ(2)=4.412，P=0.036）、肿瘤浸润深度（χ(2)=64.306，P<0.001）、组织学类型（χ(2)=8.026，P=0.005）、碱性磷酸酶（χ(2)=8.217，P=0.004）、谷氨酰转肽酶（χ(2)=33.207，P<0.001）、总胆红素（χ(2)=14.012，P<0.001）和乳酸脱氢酶（χ(2)=63.630，P<0.001）的差异均有统计学意义。LSR<1.43组和LSR≥1.43组1、3、5年生存率分别为70.8%、31.3%、25.0%和64.9%、24.4%、11.3%，两组比较差异有统计学意义（χ(2)=10.140，P=0.001）。单因素分析显示，年龄、血红蛋白水平、肿瘤TNM分期、肿瘤浸润深度、淋巴结转移率、淋巴结转移、组织学类型、肿瘤长径、谷氨酰转肽酶、总胆红素和LSR是影响胃癌患者预后的相关因素（均P<0.05）；多因素分析显示，肿瘤TNM分期（HR=1.605，95%CI：1.332~1.936，P<0.001）、肿瘤浸润深度（HR=1.299，95%CI：1.168~1.445，P<0.001）、淋巴结转移率（HR=2.400，95%CI：1.873~3.076，P<0.001）、淋巴结转移（HR=1.263，95%CI：1.106~1.478，P=0.007）、肿瘤长径（HR=1.375，95%CI：1.134~1.669，P=0.001）和LSR（HR=1.427，95%CI：1.190~1.711，P<0.001）是影响胃癌患者预后的独立危险因素。 结论： LSR是胃癌患者预后的独立危险因素，且检测简单易行，是胃癌预后的潜在标志物。因此，在术前综合治理阶段，应尽可能恢复和提高肝功能状态有助于改善胃癌患者预后，延长患者生存时间。.
Keywords: Alanine aminotransferase; Aspartate aminotransferase; Liver function; Prognosis; Stomach neoplasms.